Rat retweeted
$HIMS Peptides+ is here-
“Sermorelin, NAD+, Glutathione, Vitamin B12, and L-Carnitine, depending on their needs as determined by their provider (now available). Access to BPC-157 and TB-500 will follow, consistent with regulatory standards.”
More than 10,000 people signed up for early access when we launched the waitlist two weeks ago for Peptides+. Starting today, they all have access to a comprehensive intake that will be the beginning of a journey with a provider to find whether a personalized treatment plan is right for them.
Clinically-guided protocols. At-home blood collection. The full support of a care team that knows you, your progress, and your goals. And 5 US-compounded treatments, with more to come soon.
It’s exactly what we think health should be: easy, personal, high-quality, supported by independent experts, and on the cutting edge of where science is going.
We can’t wait to see where those journeys take you.
Read more here, including important info: investors.hims.com/news/news…
$HIMS figured out how to get existing members to pay more (massive ARPU increase)
And you are besrish?
Retards
7
349
The ticker is $HIMS
TRUMP: "I have decided that I have to break the (pharmaceutical) system. Because it is the most powerful lobby in the world. enormously powerful.
They have great influence over the Senate, the House of Representatives, and the governors.
16
1,595
Rat retweeted
[read about what’s happening with AI]
ME: Wow we’re actually legit fucked this is so bad.
[go outside]
ME: Wait those people are all acting like nothing unusual is happening. Maybe I was just in a paranoid bubble? Yeah it must be that. Phew.
[read more about what’s happening with AI]
ME: Wait no we ARE fucked. Shit. It’s all those people outside who are in a delusional bubble.
[go outside]
ME: Wait...
$HIMS international expansion is underappreciated
🚨 $HIMS ACCELERATED ITS $1 BILLION INTERNATIONAL REVENUE TARGET BY YEARS!
One of the biggest takeaways from Hims & Hers' Q3 2026 earnings call that I haven't seen many people discussing is how quickly management's international growth expectations have accelerated
• February 2026: $1B in annual international revenue by 2030.
• August 2026: $1B in annual international revenue within three years (~2029).
• November 2026: Expects to surpass a $1B international annualized revenue run rate in 2027!
That is a MASSIVE acceleration from the company's original expectations.
International revenue reached $233.3M in Q3, growing 321% YoY and approximately 78% QoQ.
At that quarterly pace, Hims is already generating approximately $933M in annualized international revenue!
Management also raised its FY2026 international revenue outlook from at least $600M to at least $650M.
Now, it's important to recognize that much of the sequential acceleration came from including a full quarter of Eucalyptus revenue following the acquisition.
However, management also highlighted nearly 80% YoY growth in its international businesses excluding Eucalyptus.
4
27
1,120
Life is fucking electric bro. Don’t fall for the doomer shit. That’s for losers and normies scared of their own shadows. Walk around like God sent you and smile at everyone you see. Spread light and abundance. Build things and take chances. This is the best time in history!
Rat retweeted
Not even the most bearish analyst has a price target as low as the current $HIMS share price
Shareholders need to get on Prozac as soon as possible
Rat retweeted
I’d like to formally invite $HIMS CEO @AndrewDudum to the pod
Would be great to have @hubermanlab on simultaneously
I think retail investors are not understanding the strategy $HIMS is executing and this pod would help
Rat retweeted
Replying to @hubermanlab
@hubermanlab is joining our Board of Directors, and he’s also joining us as an advisor to help us do for our customers what he’s done for millions of people: make the latest health science accessible and actionable.
From @AndrewDudum: “As we continue to build the future of personalized, science-backed healthcare, his expertise in neuroscience and human health will sharpen how we think about the science behind our offerings.”
Read more here, including important info: news.hims.com/newsroom/dr-an…
Andrew Haubermsn join $HIMS Board of Directors, great earnings report, and price drops
Lol this is too good more free shares
$NAUT is the modern day Avengers
CEO and co founder with multi billion dollar big data exit
CFO bossgirl with unofficial COO title
Chief Scientist and co founder genius
These 3 are running a soon to be generational company.
The people behind your ticker are everything.
The scientists working under Mallick are top tier.
@NautilusBio is an exceptional company that will leave its mark in the world.
$NAUT
14
569
Rat retweeted
People deserve to have access to the most innovative treatments. That’s why we work with leaders across the industry, and starting today, that includes @EliLillyandCo.
When innovators work together, it’s better for everyone. Customers can access more personal care, providers have a well-rounded picture of how their patients are doing, and drugmakers can be confident that the people who need their medications the most will be able to get their hands on it and stick to it.
Lilly is one of the most innovative companies in the world, and we share a commitment to reaching real people with real impact. Working together means we can combine some of the world’s best medicines with our powerful platform to help more people feel great.
Read more, including important info: news.hims.com/newsroom/lilly…
GG
$DUOL
$DUOL is on track to become the world’s dominant superhuman personal AI tutor. It will outperform any human teacher on Earth, run at a fraction of the cost, and become the platform the rest of the education market builds on top of.
Q3 2026 just confirmed the engine is working. Here’s the chain:
1/ More learners. Duolingo averaged 64.9M daily active users in Q3, up 29% year over year. That’s the second straight quarter of acceleration. The “AI kills language apps” bear case needed DAU growth to keep falling. Instead it bottomed at 21% in Q1 and is heading back towards 30%.
2/ Record net adds, against seasonality. Duolingo added 6.2M DAUs in a quarter that is usually its weakest, roughly double a typical Q3. Users aren’t leaving for chatbots. They’re coming to the product that already turns AI into daily learning.
3/ Every learner becomes a source of learning-outcome data. Every lesson, every mistake, every streak, every before-and-after across millions of people, every single day. That is data no general-purpose LLM can access, and it compounds with every new user.
4/ The data makes the tutor better. Better prediction of what each person needs next, at lower cost per lesson. Better outcomes attract more learners. More learners generate more data. Every new customer makes the tutor smarter, and every improvement in the tutor attracts more customers.
5/ Monetization follows the users. Subscription bookings growth went from 10% to 16% in a single quarter. Users lead, bookings follow, and revenue follows bookings with a lag. The market priced the lagging indicator and missed the leading one.
6/ The cash is already compounding. LTM free cash flow per share went from $0.2 in Q4 2021 to $8.3 today, on $1.18B of LTM revenue. This isn’t a speculative AI story waiting for a business model. It’s a cash machine funding its own superintelligence.
7/ Eventually the tutor becomes superhuman. It’s personalised to every learner, patient at 3am, fluent in every subject, and it runs at a fraction of the cost of a human. The best private tutor on Earth used to be a luxury for a few thousand families. Duolingo is turning it into a subscription for hundreds of millions.
8/ Then the market inverts. Schools, tutoring firms, edtech apps and employers stop competing with the tutor and start building on top of it. If you don’t own the AI trained on the largest dataset of human learning outcomes, you depend on whoever does.
Just as $PLTR became the operating system for decisions, $DUOL becomes the operating system for learning.
The molecule was the output in healthcare. Here, the lesson is the output.
The intelligence that designs it becomes the asset.
99
GG
$HIMS
$HIMS just became a two-sided operating system for healthcare. Today, Eli Lilly signed a formal partnership to distribute Zepbound and Foundayo through the $HIMS platform. Earlier this year, Novo Nordisk did the same with Wegovy. The two companies that dominate obesity medicine now both supply through $HIMS.
This is the moment the flywheel grows a second side. Here's how it works:
1/ The supply side: pharma. Building a direct-to-consumer channel is slow, expensive and outside pharma's core skill. $HIMS already has the patients, the providers, the pharmacy logistics and the brand. Lilly plugs in and reaches millions of self-pay patients without building any of it. Lower cost to reach each patient means a higher return on every drug they've already spent billions developing.
2/ The demand side: patients. A patient opens one app and gets a consultation, a prescription if appropriate, and home delivery. Foundayo starts at $149/month and Zepbound at $299/month, branded and FDA-approved, with no compounded substitutes. More choice, lower friction, same price as anywhere else. Outcomes per dollar go up.
3/ The two sides feed each other. Every new pharma partner makes the platform more valuable to patients: wider catalog, better prices, more options for the provider to match to each person. Every new patient makes the platform more valuable to pharma: more reach, more demand, more real-world data on adherence and response.
4/ The data is where it compounds. Every consultation, every check-in, every lab panel, every switch from one therapy to another becomes longitudinal outcome data that no single drugmaker can collect on its own. Patients get treatment matched to them. Pharma learns what works, for whom, in the real world.
5/ This is why both sides improve outcomes per dollar at once. Pharma gets more outcome per R&D dollar because its drugs reach the right patients at a fraction of the distribution cost. Patients get more outcome per healthcare dollar because the platform matches them to the best intervention at the best price.
6/ Then the gravity flips. The more pharma supplies through $HIMS, the more patients come. The more patients come, the more pharma has to supply through $HIMS. Lilly and Novo are fierce competitors, and both just chose the same platform. That's what a two-sided network looks like in its early innings.
7/ Now add the biomarker loop. Generic peptides arrive on the same rails. The dataset deepens. The AI gets better at designing the right intervention for each person. Eventually pharma isn't just selling through $HIMS. It's building for it.
Just as $PLTR became the operating system for enterprise decisions, $HIMS is becoming the operating system where medicine meets the patient.
The molecule becomes the output. The platform that matches it to each human becomes the asset.
91



























